Additional file 5: Table S2. of Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial

Singh, Dave; Worsley, Sally; Zhu, Chang-Qing; Hardaker, Liz; Church, Alison

doi:10.6084/m9.figshare.c.3642377_D6.v1

12890_2015_92_MOESM5_ESM.doc (37.5 kB)

Additional file 5: Table S2. of Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial

journal contribution

posted on 2015-08-19, 05:00 authored by Dave Singh, Sally Worsley, Chang-Qing Zhu, Liz Hardaker, Alison Church

Results from the analyses reporting proportions of patients achieving lung function improvements for selected other endpoints (ITT population). (DOC 37Â kb)

History

Usage metrics

Keywords

Additional propionate fluticasone proportion 2.Umeclidinium COPD lung function improvements ITT population analyses randomised trial Results DOC 37Â kb endpoints

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 5: Table S2. of Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial

History

Usage metrics

Categories

Keywords

Licence

Exports